Major Salivary Gland Tumours

46 Major Salivary Gland Tumours


46.1 Benign Tumours


• Pleomorphic adenoma—most common in parotid, 1% risk of malignant change per year after 10 years


• Warthin (papillary cystadenoma lymphomatosum)—smoking risk factor, 10% bilateral, M:F 5:1


• Monomorphic adenoma—most common is basal cell adenoma


• Oncocytomas—more common in elderly


46.2 Parotid Tumours


• 80% benign


• Most common pleomorphic adenoma


• Investigations


figure Fine needle aspiration (FNA) ± US guided


– Pros—preop planning and patient counselling


– Cons—most likely treatment is surgical so result does not change plans


figure CT/MRI


– Pros—deep lobe component can be identified, good for preop planning and counseling; lymph nodes not detected clinically may be identified therefore affecting treatment plan; infiltrative margins may raise possibility of malignancy


– Cons—if no nodes palpable, unlikely to change treatment


46.3 Submandibular Tumours


• 50% benign


• Investigations


figure FNA ± US guided


– Pros—treatment planning


– Cons—management of non-diagnostic samples; some laboratories require larger cellular volumes to diagnose lymphomas


46.4 Minor Salivary Gland Tumours


• 25% benign


• Can occur within sinuses, nasal cavity, and larynx


• Investigations


figure Biopsy under local anaesthetic or general anaesthetic


figure CT/MRI to evaluate the extent of tumour and nodal status


46.5 General Notes on Salivary Gland Malignancy


• Epidemiology


figure 1 to 2/100,000


figure 3 to 4% total head and neck malignancy


figure 25% parotid, 50% SM glands, 75% minor salivary glands


figure Risk factors include: RT exposure and occupational silica dust (blast furnaces, cement, glass, ceramic, and clay industries) and nitrosamine (rubber and tire industries)


figure Mucoepidermoid most common (inc. children)


figure In children 65% tumours are benign, with haemangiomas being the most common


• Presentation


figure Typically painless neck swelling


figure CN VII n weakness indicative of malignancy


figure Malignancy normally >6th decade


figure Benign tumours normally >4th decade


46.6 Malignant Tumours


• Mucoepidermoid carcinoma—most common malignant tumour, graded: low, medium, high


• Adenoid cystic carcinoma—most common submandibular gland malignancy, increased risk perineural invasion, lung metastases more common than nodal


• Acinic cell carcinoma—low-grade neoplasm, late recurrences even after 30 years


• Adenocarcinoma—classified into low- and high-grade types


• Squamous cell carcinoma—consider lymph node metastases from melanoma, skin


• Carcinoma ex-pleomorphic adenoma—longstanding history of parotid swelling with rapid increase in size, aggressive, 5-year survival 40%


• Salivary duct carcinoma—poor prognosis, 50% present with nodal metastases


• Lymphoma—may require trucut biopsy to diagnose


46.6.1 Staging of Salivary Gland Malignancies


• See Table 46.1


• T1—≤2 cm


• T2—2 to 4 cm


• T3—extraparenchymal extension without VII n involvement and <6 cm


• T4—invades skull base, VII n and/or >6 cm


46.6.2 Presentation of Facial Nerve Paralysis in Malignant Tumours


• Poorly differentiated carcinoma—23 to 26%


• Adenoid cystic carcinoma—23 to 26%


• Carcinoma ex-pleomorphic adenoma—9 to 14%


• Acinic cell carcinoma 3%


46.6.3 Treatment for Parotid Malignancy


• Most common is surgery ± postoperative radiotherapy (PORT)


• Operations include:


figure Superficial parotidectomy + VII n preservation


figure Total parotidectomy ± excision of VII n + grafting


– ± Excision skin with free flap or keystone repair


– ± Neck dissection


– ± Pinnectomy


– ± Petrosectomy


– ± Temporomandibular joint excision


46.6.4 Treatment for Submandibular Malignancy


• Most common is surgery ± PORT


figure Submandibular gland excision ± neck dissection


46.6.5 Treatment for Minor Salivary Gland Malignancy


• Dependent on site of tumour may require jaw split


Stay updated, free articles. Join our Telegram channel

Jul 4, 2016 | Posted by in OTOLARYNGOLOGY | Comments Off on Major Salivary Gland Tumours

Full access? Get Clinical Tree

Get Clinical Tree app for offline access